Loading…
Loading grant details…
| Funder | European Commission |
|---|---|
| Recipient Organization | Crannmed Ltd |
| Country | Ireland |
| Start Date | May 01, 2022 |
| End Date | Nov 30, 2024 |
| Duration | 944 days |
| Number of Grantees | 1 |
| Roles | Coordinator |
| Data Source | European Commission |
| Grant ID | 190167448 |
EmboSure is a breakthrough treatment for Knee Osteoarthritis.
It acts directly on the mechanism of Osteoarthritis, delivers long term pain relief and stops the progression of the disease for up to 5-years.
The solution involves embolising or blocking the tiny blood vessels of the knee with patented bioresorbable particles developed by CrannMed.
The bioresorbable embolic particles are tightly calibrated 200µm particles, made from naturally occurring biocompatible materials which block the small blood vessels of the knee over a five day period. This disrupts the osteoarthritic degradation before the particles are completely reabsorbed into the body.
The particles are delivered through a minimally invasive microcatheter, specifically designed by CrannMed to reach the tortuous vessels of the knee.
As the maintenance of blood supply to the knee and the lower leg is critical, the bioresorbable particles and microcatheter are key to our paradigm to treat without leaving anything behind.
Crannmed Ltd
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant